Please enable JavaScript.
Coggle requires JavaScript to display documents.
Vedolizumab, CORTICOSTEROID-FREE CLINICAL REMISSION AT WEEK 52 = Assessed…
Vedolizumab
-
-
GEMINI-1
-
SECONDARY ENDPOINTS
-
-
-
Anti - TNF naïve vs anti-TNF failure subpopulation: 46% in naïve population vs 19% placebo and 37% in failure populations vs 5% placebo
MECHANISM OF ACTION
Vedo preferentially binds to α4β7 on specific T Lymphocytes blocks integrin interaction with MAdCAM-1. MAdCAM-1 is specifically expressed in mucosal endothelial cells therefore targeting this protein inhibits selectively T cell migration in to inflamed gut mucosa
-
CORTICOSTEROID-FREE CLINICAL REMISSION AT WEEK 52 = Assessed in the subgroup of patients who were receiving corticosteroids at baseline and who were in clinical response at Week 6 (n=72 for placebo and n=70 for Entyvio Q8W). Corticosteroid-free clinical remission was defined as the proportion of patients in this subgroup who discontinued corticosteroids by Week 52 and were in clinical remission at Week 52.